Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion of the first dosing in a global multi-center Phase III study for its Claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate (ADC) CMG901 (AZD0901). The ADC is being evaluated as a treatment for advanced solid tumors in the second-line and later settings.
CMG901 marks a significant milestone as the world’s first CLDN18.2-targeted ADC to enter clinical trials in both China and the United States. The drug candidate is owned by KYM Bio, a joint venture between Lepu Biopharma Co., Ltd (2157.HK) and Keymed, with ownership stakes of 30% and 70%, respectively. CMG901 comprises an anti-CLDN18.2 monoclonal antibody, a protease-degradable linker, and the cytotoxic small molecule monomethyl auristatin E (MMAE).
In February 2023, AstraZeneca, a major UK pharmaceutical company, entered into a licensing agreement with both Lepu Biopharma and Keymed, securing global research and development, manufacturing, and commercialization rights for the drug.- Flcube.com
